» Articles » PMID: 21964025

IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells

Overview
Journal J Immunol
Date 2011 Oct 4
PMID 21964025
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Excessive inflammation during bacterial and viral infections is destructive to the host and involves elevated production of proinflammatory cytokines. It is especially deleterious in organs with space constraints such as lung and the CNS. Indeed, a number of viruses that infect lungs, such as avian influenza virus, SARS-associated coronavirus, and respiratory syncytial virus, elicit a very high level of proinflammatory cytokines; however, it is unclear what triggers their production. In this study, we show that IL-17 commonly produced during viral infection specifically augments a proinflammatory response by directly synergizing with antiviral signaling. Costimulation of primary human fibroblasts with IL-17 greatly enhanced respiratory syncytial virus-induced or synthetic dsRNA-based viral mimic polyinosinic:polycytidylic acid-induced expression of proinflammatory genes without affecting expression of IFN-β-stimulated or IFN-stimulated genes. Knockdown of expression of known mediators of the antiviral signaling pathway revealed that the IL-17-poly(I:C) synergy depends on the presence of the transcriptional factors RelA and IFN regulatory factor 3 and IκB kinases. Moreover, this synergy was blocked by an IκB kinase inhibitor, BAY 11-7082. These findings shed light on the molecular mechanisms behind IL-17-dependent immunopathology observed in viral infections.

Citing Articles

Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis.

Li G, Hao Z, Wang H, Wang C, Liu D, Chen L World J Otorhinolaryngol Head Neck Surg. 2025; 11(1):102-115.

PMID: 40070503 PMC: 11891286. DOI: 10.1002/wjo2.185.


Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.

Zendejas-Hernandez U, Alcantara-Martinez N, Vivar D, Valenzuela F, Sosa Espinoza A, Cervera Ceballos E Front Immunol. 2024; 14:1282280.

PMID: 38283346 PMC: 10811189. DOI: 10.3389/fimmu.2023.1282280.


Age-dependent immune responses in COVID-19-mediated liver injury: focus on cytokines.

Aghamohamadi N, Shahba F, Mehrabadi A, Khorramdelazad H, Karimi M, Falak R Front Endocrinol (Lausanne). 2023; 14:1139692.

PMID: 37654571 PMC: 10465349. DOI: 10.3389/fendo.2023.1139692.


Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).

Bonifacio L, Ramacciotti E, Agati L, Vilar F, Silva A, Junior P Rev Soc Bras Med Trop. 2023; 56:e0565.

PMID: 37075454 PMC: 10109354. DOI: 10.1590/0037-8682-0565-2022.


Vitamin B12 attenuates leukocyte inflammatory signature in COVID-19 methyl-dependent changes in epigenetic markings.

Cassiano L, Cavalcante-Silva V, Oliveira M, Prado B, Cardoso C, Salim A Front Immunol. 2023; 14:1048790.

PMID: 36993968 PMC: 10040807. DOI: 10.3389/fimmu.2023.1048790.